Abstract: The disclosure provides an anti-aging method. The method includes applying JWA gene to produce or screen anti-aging products, or products associated with treatment of aging-related diseases, or anti-oxidation products, or products for maintaining homeostasis, or products associated with diagnosis of aging or aging-related diseases, or agonists of the JWA gene.

Abstract: A prediction system for identifying key heterogeneous molecules that drive tumor metastasis including an input module, an analysis module, and an output module. The input module is configured to input a first quantitative analysis result of proteins and a second quantitative analysis result of proteins; the first quantitative analysis result of proteins is a collection of quantitative analysis results of various protein expression levels in tumor metastases of a target patient before drug intervention, and the second quantitative analysis result of proteins is a collection of quantitative analysis results of various protein expression levels in residual tumor metastases of the target patient after drug intervention. The analysis module includes a primary analysis submodule, a secondary analysis submodule, and a calculation and sorting submodule. The primary analysis submodule is used for preliminary screening analysis. The output module is used to output a sorted list of heterogeneous molecules.

Abstract: The present invention provides a compound and use thereof, particularly a JWA gene agonist and use thereof in preventing or treating radiation damage. The compound, by means of activating JWA gene expression, enhances the DNA repair capacity of cells, and has a good elimination capacity for highly active oxygen species generated by X-ray radiation. The compound can also effectively inhibit cell apoptosis caused by radiation to reduce the damage, and further reduce the generation of free radicals to reduce the probability of radiation damage.

Abstract: A method for treating or preventing alopecia including administering a patient in need thereof a pharmaceutical composition including a polypeptide. The peptide has an amino acid sequence I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z; S represents phosphorylated serine; X and Z independently represent an amino acid or an amino acid sequence; X is selected from F, (R)9, (R)9-F, 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9, 6-aminohexanoic acid-(R)9-F; and Z is selected from (G)n-RGD or A-(G)n-RGD, where n is an integer greater than or equal to 0, in the range of 0-10.

Abstract: A prediction system for identifying key heterogeneous molecules that drive tumor metastasis including an input module, an analysis module, and an output module. The input module is configured to input a first quantitative analysis result of proteins and a second quantitative analysis result of proteins; the first quantitative analysis result of proteins is a collection of quantitative analysis results of various protein expression levels in tumor metastases of a target patient before drug intervention, and the second quantitative analysis result of proteins is a collection of quantitative analysis results of various protein expression levels in residual tumor metastases of the target patient after drug intervention. The analysis module includes a primary analysis submodule, a secondary analysis submodule, and a calculation and sorting submodule. The primary analysis submodule is used for preliminary screening analysis. The output module is used to output a sorted list of heterogeneous molecules.

Abstract: The disclosure provides an anti-aging method. The method includes applying JWA gene to produce or screen anti-aging products, or products associated with treatment of aging-related diseases, or anti-oxidation products, or products for maintaining homeostasis, or products associated with diagnosis of aging or aging-related diseases, or agonists of the JWA gene.

Abstract: An anti-tumor polypeptide, having an amino acid sequence represented by FPGSDRF (SEQ ID NO: 15), X-FPGSDRF (SEQ ID NO: 16), FPGSDRF-Z (SEQ ID NO: 17), or X-FPGSDRF-Z (SEQ ID NO: 18) is disclosed. The various capital letters denote amino acids: F: phenylalanine; P: proline; G: glycine; D: aspartic acid; R: arginine; S is a phosphorylated serine residue, X and Z are an amino acid residue or an amino acid sequence, respectively, X is one selected from the group consisting of F, (R)9 (SEQ ID NO: 19), (R)9-F (SEQ ID NO: 20), 6-aminocaproic acid, 6-aminocaproic acid-F, 6-aminocaproic acid-(R)9 (SEQ ID NO: 21), and 6-aminocaproic acid-(R)9-F (SEQ ID NO: 22), Z is one selected from the group consisting of A, (G)n-RGD (SEQ ID NO: 23), and A-(G)n-RGD (SEQ ID NO: 24); and n is an integer greater than or equal to 0.

Abstract: An anti-tumor polypeptide, having an amino acid sequence represented by FPGSDRF (SEQ ID NO. 15), X-FPGSDRF, FPGSDRF-Z, or X-FPGSDRF-Z, in which the various capital letters denote amino acids: F: phenylalanine; P: proline; G: glycine; S: serine; D: aspartic acid; R: arginine; S is a phosphorylated serine residue, X and Z are an amino acid residue or an amino acid sequence, respectively, X is one selected from the group consisting of F, (R)9, (R)9-F, 6-aminocaproic acid, 6-aminocaproic acid-F, 6-aminocaproic acid-(R)9, and 6-aminocaproic acid-(R)9-F, Z is one selected from the group consisting of A, (G)n-RGD, and A-(G)n-RGD; and n is an integer greater than or equal to 0.